Biogen Inc. agreed to buy an early-stage experimental treatment from Pfizer Inc. to test in patients with Alzheimer’s and Parkinson’s disease.
Eagle Pharmaceuticals Inc. and the University of Pennsylvania agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease.
Amarin Corporation plc announced the launch of True To Your Heart, an educational campaign to help people learn more about cardiovascular disease and how to better protect against persistent cardiovascular risk.
For the second year in a row, Healthline was named one of Ad Age’s Top 5 Best Places to Work for 2020 for companies with 200+ employees. “
AstraZeneca said on Monday the company will discontinue a late-stage trial for the heart disease drug Epanova to treat patients with mixed dyslipidemia and expects a $100 million writedown to hit its core profit in the fourth quarter.
MorphoSys AG and Incyte Corporation inked a collaboration and license deal to further develop and commercialize MorphoSys’ anti-CD19 antibody tafasitamab around the world.
Roche will utilize Amunix Pharmaceuticals’ XTEN technology platform to identify and develop non-cancer therapies against specific undisclosed targets.
Pharma is in digital hyperdrive, and the job market looks nothing like it did in the past. Pharma marketers who ignore changes risk losing their competitive edge.
Eli Lilly and Co. is buying skin disease specialist Dermira Inc. for about $1.1 billion in cash, bolstering the Indianapolis-based drug manufacturer’s arsenal with an experimental therapy for the skin condition atopic dermatitis.
Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.